ClinicalTrials.gg
Active, not recruitingNCT04817241Updated Nov 3, 2026Results posted

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

A Phase 1/2 interventional study of Biospecimen Collection and Bone Marrow Aspiration and Biopsy in Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI). Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 203 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 145 under way, 22 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
194th of 203
5 · median 58
Started
2022
with 30 others
Phase 1/2
28 of 203
12 open now
Primary completion
2025-06
later than 18 of 144 live
Registered
62nd of 203
by date
Lead sponsor
13 of 203
National Cancer Institute (NCI)

Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 194th largest by enrollment, is one of 31 that started in 2022, is one of 28 in phase 1/2, reaches primary completion later than 18 of the 144 other live ones, and was the 62nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 203 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called fms-like tyrosine kinase 3 (FLT3). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is an enzyme inhibitor. It helps to increase the amount of decitabine in the body so that the medication will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Venetoclax and decitabine are commonly given together for older patients with AML ASTX727 (a pill form of decitabine + cedazuridine) has been found to be equal to decitabine (given intravenously), and this part of the study is to confirm that venetoclax and ASTX727 is as safe as venetoclax and decitabine given intravenously. This study allows for lowering doses of study drugs to assure the dose chosen for the randomized study (second portion of this trial) is safe and tolerable for people. Giving ASTX727 in combination with venetoclax may help in the treatment of patients with higher-risk acute myeloid leukemia.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine and compare the preliminary efficacy of venetoclax +ASTX727 versus (vs.) standard anthracycline induction therapy ('7+3') with a primary endpoint of event-free survival (EFS).

SECONDARY OBJECTIVES:

I. To determine the complete response (complete response [CR] + complete response with incomplete bone marrow recovery [CRi]) rate in patients with treatment naive FLT3 wild type (WT) acute myeloid leukemia (AML) treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').

II. To determine the duration of response (DoR) in patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').

III. To determine the progression free survival (PFS) of patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').

IV. To determine the overall response rate (ORR) in patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').

V. To determine the overall survival (OS) of patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').

VI. To determine the proportion of patients receiving stem cell transplantation (SCT) in patients with treatment naive FLT3WT AML treated with venetoclax and ASTX727 vs. standard anthracycline induction therapy ('7+3').

VII. To identify mutational burdens in venetoclax +ASTX727 sensitive vs. resistant AML leukemia initiating cells (LICs).

EXPLORATORY OBJECTIVES:

I. To identify transcriptomic signatures in venetoclax +ASTX727 sensitive vs. resistant AML LICs.

II. Determine the utility of high-throughput phenotype-based assessment of drug efficacy for predicting patient response to venetoclax +ASTX727.

III. Determine if treatment failure is a function of therapy sequence or results in resistance to the alternative therapy by conducting a co-clinical trial via patient-derived xenograft (PDX).

IV. To characterize the pharmacokinetics of venetoclax. V. To determine the morphologic leukemia-free state (MLFS) rate in patients with treatment naïve FLT3WT AML treated with venetoclax and ASTX727 vs. 7+3 therapy.

OUTLINE: This is a phase Ib dose de-escalation study followed by a phase II randomized study.

PHASE Ib: Patients receive ASTX727 (decitabine and cedazuridine) orally (PO) once daily (QD) on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.

ARM II: Patients receive cytarabine intravenously (IV) over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.

After completion of study treatment, patients are followed up every 3 months for up to 2 years.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be between 18-65 years of age at the time of signing the Form (ICF) and must be able to meet all study requirements. AML patients under the age of 18 are excluded as is being studied in patients under 18 years of age in different venues
  • Morphologically confirmed diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria
  • Adverse risk AML per 2017 European LeukemiaNet (ELN) recommendations
  • Subjects must be either treatment naive defined by =\< 1 cycle of deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) therapy, no history of cytotoxic chemotherapy for their AML; prior treatment with lenalidomide, hydroxyurea or erythropoiesis-stimulating agents (ESAs) is allowed (prior treatment for myelodysplastic syndrome [MDS] with > 1 cycle of DNMTi is not allowed)
  • A bone marrow aspirate and must be performed, and tissue collected for entrance to the trial
  • (ECOG) performance status =\< 2 ( >= 60%)
  • Recovery to =\< grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia
  • White blood cell count (WBC) \< 25,000 (may be reduced with leukapheresis or hydroxyurea prior to study start)
  • Direct =\< 2 x institutional (ULN)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 3 x institutional ULN
  • >= 30 mL/min (per the Cockcroft-Gault formula)
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment or have received treatment, they are eligible if they have an undetectable HCV viral load
  • Tumor lysis present prior to therapy must be treated accordingly prior to start of therapy
  • The effects of venetoclax and ASTX727 on the developing human fetus are unknown. For this reason and because BCL2 inhibitor and DNMTi agents as well as other therapeutic agents used in this trial (cytarabine and daunorubicin) are known to be teratogenic, women of must agree to use adequate (hormonal method of birth control or abstinence) prior to study entry and for the duration of study participation, and for 6 months following completion of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception (latex or synthetic condom or abstinence) prior to the study, for the duration of study participation, and 3 months after completion of venetoclax and ASTX727 administration
  • Ability to understand and the willingness to sign a written informed consent document
  • Adequate cardiac systolic function as measured by (EF) >= 50%

Exclusion criteria

Exclusion Criteria:

  • Favorable or intermediate risk AML as defined by 2017 ELN criteria
  • Presence of FLT3 TKD or FLT-ITD mutations
  • Inability to tolerate oral medication or keep a pill diary
  • Active documented central nervous system (CNS) leukemia
  • Concurrent treatment with a non-permitted concomitant medication
  • Concurrent anticancer treatment, major surgery, or use of any drug within 28 days before the start of trial treatment
  • Other currently being treated or likely to be treated in next 6 months with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ and patients receiving hormonal therapy for prevention of hormone-sensitive cancers
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to venetoclax, ASTX727, or other agents used in study
  • Patient must not have received known moderate or strong inducers within 7 days of enrollment. Patient must not have known medical conditions requiring chronic therapy of moderate CYP3A inducers. As part of the enrollment/ procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations (including substance abuse) that would limit compliance with study requirements
  • Pregnant women are excluded from this study because venetoclax and ASTX727 have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax. These potential risks may also apply to other agents used in this study
  • Previous exposure to either venetoclax or > 1 cycle of DNMTi (e.g. azacitidine, decitabine, ASTX727, CC486)
  • Active, uncontrolled infection as determined by the investigator. Patients with infection under active treatment and controlled with antibiotics are eligible
  • Any condition deemed by the investigator to make the patient a poor candidate for clinical trial and/or treatment with investigational agents
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Arm I (decitabine and cedazuridine, venetoclax)

    Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Drug: Decitabine and Cedazuridine · Drug: Venetoclax

  • Active comparator
    Arm II (cytarabine, daunorubicin)

    Patients receive cytarabine IV over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.

    Procedure: Bone Marrow Aspiration and Biopsy · Drug: Cytarabine · Drug: Daunorubicin

  • Experimental
    Phase Ib (decitabine and cedazuridine, venetoclax)

    Patients receive ASTX727 PO QD on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Drug: Decitabine and Cedazuridine · Drug: Venetoclax

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Aspiration and Biopsy

    Undergo bone marrow aspiration and biopsy

  • Given IV

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • Given IV

    Also known as: Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C

  • DrugDecitabine and Cedazuridine

    Given PO

    Also known as: ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi

  • Given PO

    Also known as: ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Recommended Safe Phase 2 Dose (RP2D) of Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax (Phase Ib)

    The highest dose level in which at most 1 patient in 6 experiences dose-limiting toxicity (DLT).

    Time frame: From start of treatment to end of first cycle (28 days)

  2. Incidence of Adverse Events (Phase Ib)

    Will be tabulated and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Summary statistics will be provided for all adverse events reported. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percent and frequencies for categorical parameters, will be presented

    Time frame: Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.

  3. Event-free Survival (EFS) (Phase II)

    Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. EFS is defined as survival without death, blasts\>20%, myeloid sarcoma, or AML in the central nervous system (CNS disease).

    Time frame: Up to 2 years after completion of study treatment

Secondary outcomes

  1. Complete Response Rate (Phase II)

    Rate of complete response (CR) + complete response with incomplete bone marrow recovery (CRi). The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery.

    Time frame: Up to 2 years after completion of study treatment

  2. Duration of Response (Phase II)

    Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.

    Time frame: Up to 2 years after completion of study treatment

  3. Progression-free Survival (PFS) (Phase II)

    The distribution of PFS will be estimated using the method of Kaplan and Meier. Hazard rate for PFS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.

    Time frame: Time from randomization date to the date of progression or death for any reason, assessed up to 2 years after completion of study treatment

  4. Overall Response Rate (Phase II)

    Rate of partial response (PR) + CRi + CR in patients with treatment naive AML treated with venetoclax and ASTX727. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.

    Time frame: Up to 2 years after completion of study treatment

  5. Overall Survival (OS) (Phase II)

    The distribution of OS will be estimated using the method of Kaplan and Meier. Hazard rate for OS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.

    Time frame: Time from randomization to death for any reason, assessed up to 2 years after completion of study treatment

  6. The Proportion of Treatment Naive AML Patients Receiving Stem Cell Transplantation (SCT) Following Treatment With Venetoclax and ASTX727 (Phase II)

    Time frame: Up to 2 years after completion of study treatment

  7. Mutational Burdens in Venetoclax + ASTX727 Sensitive vs. Resistant AML Leukemia Initiating Cells (LICs) (Phase II)

    Time frame: Up to 2 years after completion of study treatment

07

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)
Started221
Completed001
Not completed220
Withdrew: Physician decision100
Withdrew: Adverse event100
Withdrew: Starting consolidation therapy off study010
Withdrew: Death010

Outcome measures

PrimaryRecommended Safe Phase 2 Dose (RP2D) of Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax (Phase Ib)

The highest dose level in which at most 1 patient in 6 experiences dose-limiting toxicity (DLT).

Time frame:
From start of treatment to end of first cycle (28 days)

No measurements were reported for this outcome.

PrimaryIncidence of Adverse Events (Phase Ib)

Will be tabulated and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Summary statistics will be provided for all adverse events reported. Descriptive statistics, including means, standard deviations, and ranges for continuous parameters, as well as percent and frequencies for categorical parameters, will be presented

Time frame:
Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.
Reported as:
Count of participants · Participants
Incidence of Adverse Events (Phase Ib)
ParticipantsPhase Ib (Decitabine and Cedazuridine, Venetoclax)
Bacteremia — Grade 10
Bacteremia — Grade 21
Bacteremia — Grade 30
Bacteremia — Grade 40
Bacteremia — Grade 50
Constipation — Grade 11
Constipation — Grade 20
Constipation — Grade 30
Constipation — Grade 40
Constipation — Grade 50
Fatigue — Grade 11
Fatigue — Grade 20
Fatigue — Grade 30
Fatigue — Grade 40
Fatigue — Grade 50
Hyperkalemia — Grade 10
Hyperkalemia — Grade 21
Hyperkalemia — Grade 30
Hyperkalemia — Grade 40
Hyperkalemia — Grade 50
Hyperuricemia — Grade 11
Hyperuricemia — Grade 20
Hyperuricemia — Grade 30
Hyperuricemia — Grade 40
Hyperuricemia — Grade 50
Lymphocyte count decreased — Grade 10
Lymphocyte count decreased — Grade 20
Lymphocyte count decreased — Grade 31
Lymphocyte count decreased — Grade 40
Lymphocyte count decreased — Grade 50
Nausea — Grade 11
Nausea — Grade 20
Nausea — Grade 30
Nausea — Grade 40
Nausea — Grade 50
Platelets count decreased — Grade 11
Platelets count decreased — Grade 20
Platelets count decreased — Grade 30
Platelets count decreased — Grade 40
Platelets count decreased — Grade 50
White blood cell decreased — Grade 10
White blood cell decreased — Grade 20
White blood cell decreased — Grade 30
White blood cell decreased — Grade 41
White blood cell decreased — Grade 50
PrimaryEvent-free Survival (EFS) (Phase II)

Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. EFS is defined as survival without death, blasts\>20%, myeloid sarcoma, or AML in the central nervous system (CNS disease).

Time frame:
Up to 2 years after completion of study treatment
Reported as:
Median · days
Event-free Survival (EFS) (Phase II)
daysArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
Event-free Survival (EFS) (Phase II)64 (15 to 113)NA (0 to 816)
SecondaryComplete Response Rate (Phase II)

Rate of complete response (CR) + complete response with incomplete bone marrow recovery (CRi). The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery.

Time frame:
Up to 2 years after completion of study treatment
Reported as:
Count of participants · Participants
Complete Response Rate (Phase II)
ParticipantsArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
Complete Response Rate (Phase II)11
SecondaryDuration of Response (Phase II)

Will be estimated using the method of Kaplan and Meier and compared among treatments and other important prognostic groups using the log-rank test. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.

Time frame:
Up to 2 years after completion of study treatment
Reported as:
Number · days
Duration of Response (Phase II)
daysArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
Duration of Response (Phase II)113821
SecondaryProgression-free Survival (PFS) (Phase II)

The distribution of PFS will be estimated using the method of Kaplan and Meier. Hazard rate for PFS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.

Time frame:
Time from randomization date to the date of progression or death for any reason, assessed up to 2 years after completion of study treatment
Reported as:
Median · days
Progression-free Survival (PFS) (Phase II)
daysArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
Progression-free Survival (PFS) (Phase II)64 (15 to 113)64 (0 to 816)
SecondaryOverall Response Rate (Phase II)

Rate of partial response (PR) + CRi + CR in patients with treatment naive AML treated with venetoclax and ASTX727. The ELN criteria was used for definitions of response: CR, Complete Remission; CRi, Complete Remission with Incomplete Blood Count Recovery, PR: partial remission.

Time frame:
Up to 2 years after completion of study treatment
Reported as:
Count of participants · Participants
Overall Response Rate (Phase II)
ParticipantsArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
Overall Response Rate (Phase II)11
SecondaryOverall Survival (OS) (Phase II)

The distribution of OS will be estimated using the method of Kaplan and Meier. Hazard rate for OS will be estimated, along with 95% confidence intervals, using the Cox (proportional hazards) regression model.

Time frame:
Time from randomization to death for any reason, assessed up to 2 years after completion of study treatment
Reported as:
Median · days
Overall Survival (OS) (Phase II)
daysArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
Overall Survival (OS) (Phase II)64 (15 to 113)NA (0 to 816)
SecondaryThe Proportion of Treatment Naive AML Patients Receiving Stem Cell Transplantation (SCT) Following Treatment With Venetoclax and ASTX727 (Phase II)
Time frame:
Up to 2 years after completion of study treatment
Reported as:
Count of participants · Participants
The Proportion of Treatment Naive AML Patients Receiving Stem Cell Transplantation (SCT) Following Treatment With Venetoclax and ASTX727 (Phase II)
ParticipantsArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)
The Proportion of Treatment Naive AML Patients Receiving Stem Cell Transplantation (SCT) Following Treatment With Venetoclax and ASTX727 (Phase II)00
SecondaryMutational Burdens in Venetoclax + ASTX727 Sensitive vs. Resistant AML Leukemia Initiating Cells (LICs) (Phase II)
Time frame:
Up to 2 years after completion of study treatment

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (Decitabine and Cedazuridine, Venetoclax)2/2 (100%)2/2 (100%)2/2 (100%)
Arm II (Cytarabine, Daunorubicin)1/2 (50%)1/2 (50%)2/2 (100%)
Phase Ib (Decitabine and Cedazuridine, Venetoclax)0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)
AppendicitisInfections and infestations0/20/21/1
BacteremiaInfections and infestations0/20/21/1
Enterobacter septicemiaInfections and infestations0/20/21/1
Failure to thriveInvestigations0/20/21/1
Febrile NeutropeniaBlood and lymphatic system disorders1/20/21/1
LethargyNervous system disorders0/20/21/1
ConfusionPsychiatric disorders1/20/20/1
Lung InfectionRespiratory, thoracic and mediastinal disorders0/21/20/1
Spleen painGeneral disorders1/20/20/1
Suspected disease progressionGeneral disorders1/20/20/1
Most frequent other events
Showing 10 of 68
Most frequent other events
EventArm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)
AnemiaBlood and lymphatic system disorders1/20/21/1
AnorexiaMetabolism and nutrition disorders1/21/21/1
Back painMusculoskeletal and connective tissue disorders1/20/21/1
ChillsGeneral disorders0/20/21/1
ConfusionPsychiatric disorders0/20/21/1
ConstipationGastrointestinal disorders2/20/21/1
Creatinine increasedInvestigations1/20/21/1
DyspneaRespiratory, thoracic and mediastinal disorders1/21/21/1
FatigueGeneral disorders2/20/21/1
Generalized body painGeneral disorders0/20/21/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)Total
<=18 years0000
Between 18 and 65 years1214
>=65 years1001
Sex: Female, Male
Sex: Female, Male(Participants)Arm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)Total
Female1113
Male1102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)Total
Hispanic or Latino0000
Not Hispanic or Latino2215
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White2215
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Arm I (Decitabine and Cedazuridine, Venetoclax)Arm II (Cytarabine, Daunorubicin)Phase Ib (Decitabine and Cedazuridine, Venetoclax)Total
United States2215
08

Study locations

7 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jun 2025, 39 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's 39 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Mar 26, 2021
StartActual
Feb 10, 2022
Primary completionActual
Jun 6, 2025
CompletionEst.
Nov 5, 2026
Results first posted
Oct 6, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 6, 2026 · revised Nov 3, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedRecommended safe phaseSafe Phase 2 doseDose (RP2D) of decitabineDecitabine and cedazuridineCedazuridine (ASTX727) in combination with venetoclaxCombination With Venetoclax (Phase Ib)Time frame: End of each cycle (1 cycle = 28 days) → From start of treatment to end of first cycle (28 days)
  • EditedIncidence of adverse eventsAdverse Events (Phase Ib)Time frame: Up to 2 years after completion of study treatment → Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.
  • EditedEvent-free survivalSurvival (EFS) (Phase II)Time frame: Up to 2 years after completion of study treatment
Oct 6, 2026
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedComplete response rateResponse Rate (Phase II)Time frame: Up to 2 years after completion of study treatment
  • EditedDuration of responseResponse (Phase II)Time frame: Up to 2 years after completion of study treatment
  • EditedProgression-free survivalSurvival (PFS) (Phase II)Time frame: Time from randomization date to the date of progression or death for any reason, assessed up to 2 years after completion of study treatment
  • EditedOverall response rateResponse Rate (Phase II)Time frame: Up to 2 years after completion of study treatment
  • EditedOverall survivalSurvival (OS) (Phase II)Time frame: Time from randomization to death for any reason, assessed up to 2 years after completion of study treatment
  • EditedThe proportionProportion of treatment naiveTreatment Naive AML patients receiving stem cell transplantationPatients Receiving Stem Cell Transplantation (SCT) following treatment with venetoclaxFollowing Treatment With Venetoclax and ASTX727 (Phase II)Time frame: Up to 2 years after completion of study treatment
  • EditedMutational burdensBurdens in venetoclaxVenetoclax + ASTX727 sensitiveSensitive vs. resistantResistant AML leukemia initiating cellsLeukemia Initiating Cells (LICs) (Phase II)Time frame: Up to 2 years after completion of study treatment
Oct 6, 2026
Show all 2 updates
  1. Nov 3, 2026
    Posted results revised
    + 3 other changes: verification date, arm descriptions and documents
  2. Oct 6, 2026
    Results posted
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedRecommended safe phaseSafe Phase 2 doseDose (RP2D) of decitabineDecitabine and cedazuridineCedazuridine (ASTX727) in combination with venetoclaxCombination With Venetoclax (Phase Ib)Time frame: End of each cycle (1 cycle = 28 days) → From start of treatment to end of first cycle (28 days)
    • EditedIncidence of adverse eventsAdverse Events (Phase Ib)Time frame: Up to 2 years after completion of study treatment → Adverse event data were collected for the first five days of treatment, weekly for the next three weeks, and then day 1 of each subsequent 4-week cycle during treatment, and up to 35 days following completion of treatment.
    • EditedEvent-free survivalSurvival (EFS) (Phase II)Time frame: Up to 2 years after completion of study treatment
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedComplete response rateResponse Rate (Phase II)Time frame: Up to 2 years after completion of study treatment
    • EditedDuration of responseResponse (Phase II)Time frame: Up to 2 years after completion of study treatment
    • EditedProgression-free survivalSurvival (PFS) (Phase II)Time frame: Time from randomization date to the date of progression or death for any reason, assessed up to 2 years after completion of study treatment
    • EditedOverall response rateResponse Rate (Phase II)Time frame: Up to 2 years after completion of study treatment
    • EditedOverall survivalSurvival (OS) (Phase II)Time frame: Time from randomization to death for any reason, assessed up to 2 years after completion of study treatment
    • EditedThe proportionProportion of treatment naiveTreatment Naive AML patients receiving stem cell transplantationPatients Receiving Stem Cell Transplantation (SCT) following treatment with venetoclaxFollowing Treatment With Venetoclax and ASTX727 (Phase II)Time frame: Up to 2 years after completion of study treatment
    • EditedMutational burdensBurdens in venetoclaxVenetoclax + ASTX727 sensitiveSensitive vs. resistantResistant AML leukemia initiating cellsLeukemia Initiating Cells (LICs) (Phase II)Time frame: Up to 2 years after completion of study treatment
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04817241
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Feb 10, 2022
Primary completion
Jun 6, 2025
Completion
Nov 5, 2026 (estimated)
Results posted
Oct 6, 2026
Last update
Nov 3, 2026

Study contacts

Michael R Savona
principal investigator · Yale University Cancer Center LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion